Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, Thomas E. Witzig, Morie Gertz, Betsy Laplant, Suzanne Hayman, John Camoriano, Martha Lacy, P. Leif Bergsagel, Stacey Chuma, Daniel Deangelo, Steven P. Treon

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia'. Together they form a unique fingerprint.

Medicine & Life Sciences